Hien Tang, PharmD, BCOP

home / authors / hien-tang-pharmd-bcop

Articles

Credit: AkuAku - stock.adobe.com

USC ALL Induction Regimen Combined With Newer TKIs Is Safe, Effective for Patients With Ph+ Disease

Amir Ali, PharmD, BCOP;Amin Khudari, PharmD Candidate;Vincent Mendiola, MD;George Yaghmour, MD;Samantha Shi, PharmD, BCOP;Hien Tang, PharmD, BCOP;Harry Shamamian, PharmD, MBA, FACHE
June 14th 2023

Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.

Read More

Monoclonal antibodies | Image credit: Dr_Microbe - stock.adobe.com

Real-World Efficacy, Safety of Tixagevimab/Cilgavimab in Patients With Cancer After EUA Revision

Ann Tong, PharmD;Yijun Cai, PharmD Candidate;Samantha Shi, PharmD, BCOP;Hien Tang, PharmD, BCOP;Harry Shamamian, PharmD, MBA, FACHE;Amir Ali, PharmD, BCOP
April 12th 2023

The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD